Rhythm Biosciences Ltd

Rhythm Bioscience tackles bowel cancer with accessible diagnostic tool

Rhythm Biosciences Ltd (ASX:RHY) managing director & CEO Trevor Lockett speaks to Proactive Investors about the health company’s development of a diagnostic tool for detecting colorectal or bowel cancer.
ColoSTAT, Rhythm’s antibody-based blood test, was granted a biomarker patent within Europe earlier this year.
“Colorectal cancer is one of the major killers globally … it’s also remarkable that colorectal cancer is one of the most curable cancers if detected early,” Lockett says.
He continues, “ColoSTAT is a blood test for bowel cancer. It’s based on the detection of proteins that change in concentration in the blood, in the situation of cancer versus normal disease. It’s designed to be a cost-effective, highly clinically effective and accessible test that will be taken by many people.”

Quick facts: Rhythm Biosciences Ltd

Price: $0.18

Market: ASX
Market Cap: $18.14 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Oneview Healthcare taking on the senior living market with...

Oneview Healthcare PLC (ASX:ONE) CEO James Fitter tells Proactive the Ireland-based company is moving into the senior living market, deploying its technology platform with Colorado-based Christian Living communities in the first half of 2020, and with a 'large operator' in Australia, to develop...

1 hour, 52 minutes ago

2 min read